Noninvasive biomarker tests diagnose urothelial cancer in patients with hematuria
“What was very impressive from the study was by sequentially using Cxbladder Triage, Detect, and Resolve, we could not only segregate those who had cancer versus not, but also those who had low-risk tumors versus high-risk tumors,” says Jay Raman, MD, FACS.
In this video, Jay Raman, MD, FACS,discusses the findings and takeaways of the study, “The diagnostic performance of Cxbladder Resolve, alone and in combination with other Cxbladder tests, in the identification and priority evaluation of patients at risk for urothelial carcinoma,” published in the Journal of Urology. Raman is a professor and chair of urology at Penn State Health Milton S. Hershey Medical Center, Penn State University, Pennsylvania.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
